1. Introduction

This started out as a simple survey to see what people thought about one specific recent regulatory action by the FDA; namely a Warning Letter sent to Novartis regarding the website for their drug, Tasigna. The main issue in the violation was content that was shared via social media. You can read more about this with comments from industry pundits here.

What I would like to know is what people INSIDE pharma companies think of this (OK, if you work for an agency, that's OK too :-). You can give me your opinions using this completely anonymous questionnaire.

Since starting this little survey, the issue has now expanded to answer a more general question; ie, What do you think of the FDA's regulatory actions in general? Feel free to spout off specifically or generally! But try to focus on FDA actions regarding social media and search engine marketing.

John Mack, Editor, Pharma Marketing News